Similar Posts
Interview With Chris Kilham, Medicine Hunter Inc.
Chris works alongside companies to develop plant-based food and medicinal products, helping turn them into market successes. He has conducted medicinal plant research and sustainable botanical sourcing in over 45 countries, and has been featured on a number of platforms such as The New York Times, The Dr. Oz Show, Business Insider, CNN, VICE, and much more.
Interview with Joe Moore, Founder & CEO of Psychedelics Today
In this episode, Joe discusses the current landscape of the industry, his thoughts on its general direction, and why we need to defund the DEA to really progress the movement overall.
Is MindMed Expanding to PSILOCYBIN? (BIG MMED / MMEDF Stock NEWS)
In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin.
Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled “MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience”. MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer.
Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project
And that project will be researching the effects of Psilocybin
So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS).
So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up.
MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel
and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine..So does this mean that MindMed’s hiring decision is related to the company’s plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed’s potential product pipeline as well as the MindMed stock.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.comhttps://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-DepressiveDISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
Exploring Healing and Embodiment: Insights from The Body Workshop
In a world where wellness encompasses more than just physical health, The Body Workshop offers a unique platform for exploring the interconnectedness of mind, body, and spirit.
Are Celebrities Helping the Psychedelic Movement?
To watch the entire Spotlight In Focus episode, visit: https://www.altrd.tv/shows/spotlight-focus/season/1/episode/2…
Interview With Douglas K. Gordon
CEO of Silo Wellness, Douglas K. Gordon, speaks about the company’s expansion to the Frankfurt Exchange and the recent collaboration with the Bob Marley Estate.
